G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 7.15 USD
Market Cap: 377.2m USD

G1 Therapeutics Inc
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

G1 Therapeutics Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
G1 Therapeutics Inc
NASDAQ:GTHX
PP&E Net
$5.6m
CAGR 3-Years
-17%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.5B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.5B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$7.2B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$3B
CAGR 3-Years
27%
CAGR 5-Years
27%
CAGR 10-Years
16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$5B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
13%
No Stocks Found

G1 Therapeutics Inc
Glance View

Market Cap
376.8m USD
Industry
Biotechnology

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

GTHX Intrinsic Value
5.88 USD
Overvaluation 18%
Intrinsic Value
Price

See Also

What is G1 Therapeutics Inc's PP&E Net?
PP&E Net
5.6m USD

Based on the financial report for Jun 30, 2024, G1 Therapeutics Inc's PP&E Net amounts to 5.6m USD.

What is G1 Therapeutics Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
14%

Over the last year, the PP&E Net growth was -23%. The average annual PP&E Net growth rates for G1 Therapeutics Inc have been -17% over the past three years , 14% over the past five years .

Back to Top